196 related articles for article (PubMed ID: 36402786)
1. Complementary anti-cancer pathways triggered by inhibition of sideroflexin 4 in ovarian cancer.
Tesfay L; Paul BT; Hegde P; Brewer M; Habbani S; Jellison E; Moore T; Wu H; Torti SV; Torti FM
Sci Rep; 2022 Nov; 12(1):19936. PubMed ID: 36402786
[TBL] [Abstract][Full Text] [Related]
2. Targeting DNA repair and replication stress in the treatment of ovarian cancer.
Murai J
Int J Clin Oncol; 2017 Aug; 22(4):619-628. PubMed ID: 28643177
[TBL] [Abstract][Full Text] [Related]
3. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
Lau CH; Seow KM; Chen KH
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
[TBL] [Abstract][Full Text] [Related]
4. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
[TBL] [Abstract][Full Text] [Related]
5. Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib via Regulation of Rad51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells.
Cho HY; Kim YB; Park WH; No JH
Cancer Res Treat; 2021 Jul; 53(3):819-828. PubMed ID: 33332934
[TBL] [Abstract][Full Text] [Related]
6. Sideroflexin 4 affects Fe-S cluster biogenesis, iron metabolism, mitochondrial respiration and heme biosynthetic enzymes.
Paul BT; Tesfay L; Winkler CR; Torti FM; Torti SV
Sci Rep; 2019 Dec; 9(1):19634. PubMed ID: 31873120
[TBL] [Abstract][Full Text] [Related]
7. Poly (ADP-ribose) polymerase (PARP) as target for the treatment of epithelial ovarian cancer: what to know.
Della Corte L; Foreste V; Di Filippo C; Giampaolino P; Bifulco G
Expert Opin Investig Drugs; 2021 May; 30(5):543-554. PubMed ID: 33724122
[TBL] [Abstract][Full Text] [Related]
8. The Current Status of DNA-Repair-Directed Precision Oncology Strategies in Epithelial Ovarian Cancers.
Tang H; Kulkarni S; Peters C; Eddison J; Al-Ani M; Madhusudan S
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108451
[TBL] [Abstract][Full Text] [Related]
9. DNA Repair Proteins as Therapeutic Targets in Ovarian Cancer.
López-Camarillo C; Rincón DG; Ruiz-García E; Astudillo-de la Vega H; Marchat LA
Curr Protein Pept Sci; 2019; 20(4):316-323. PubMed ID: 30215333
[TBL] [Abstract][Full Text] [Related]
10. Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?
Klotz DM; Wimberger P
Arch Gynecol Obstet; 2020 Nov; 302(5):1087-1102. PubMed ID: 32833070
[TBL] [Abstract][Full Text] [Related]
11. CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors.
Lu X; He Y; Johnston RL; Nanayakarra D; Sankarasubramanian S; Lopez JA; Friedlander M; Kalimutho M; Hooper JD; Raninga PV; Khanna KK
J Exp Clin Cancer Res; 2022 Dec; 41(1):355. PubMed ID: 36539830
[TBL] [Abstract][Full Text] [Related]
12. Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.
Gupta VG; Hirst J; Petersen S; Roby KF; Kusch M; Zhou H; Clive ML; Jewell A; Pathak HB; Godwin AK; Wilson AJ; Crispens MA; Cybulla E; Vindigni A; Fuh KC; Khabele D
Gynecol Oncol; 2021 Jul; 162(1):163-172. PubMed ID: 33867143
[TBL] [Abstract][Full Text] [Related]
13. HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer.
Ma H; Qi G; Han F; Lu W; Peng J; Li R; Yan S; Yuan C; Kong B
Cell Death Dis; 2022 Mar; 13(3):263. PubMed ID: 35332131
[TBL] [Abstract][Full Text] [Related]
14. LCK facilitates DNA damage repair by stabilizing RAD51 and BRCA1 in the nucleus of chemoresistant ovarian cancer.
Dey G; Bharti R; Braley C; Alluri R; Esakov E; Crean-Tate K; McCrae K; Joehlin-Price A; Rose PG; Lathia J; Gong Z; Reizes O
J Ovarian Res; 2023 Jun; 16(1):122. PubMed ID: 37370140
[TBL] [Abstract][Full Text] [Related]
15. Appropriate Selection of PARP Inhibitors in Ovarian Cancer.
Smith M; Pothuri B
Curr Treat Options Oncol; 2022 Jun; 23(6):887-903. PubMed ID: 35412195
[TBL] [Abstract][Full Text] [Related]
16. Difluoromethylornithine (DFMO) Enhances the Cytotoxicity of PARP Inhibition in Ovarian Cancer Cells.
El Naggar O; Doyle B; Mariner K; Gilmour SK
Med Sci (Basel); 2022 May; 10(2):. PubMed ID: 35736348
[TBL] [Abstract][Full Text] [Related]
17. Breaking the Iron Homeostasis: A "Trojan Horse" Self-Assembled Nanodrug Sensitizes Homologous Recombination Proficient Ovarian Cancer Cells to PARP Inhibition.
Li Y; Cen Y; Fang Y; Tang S; Li S; Ren Y; Zhang H; Lu W; Xu J
ACS Nano; 2022 Aug; 16(8):12786-12800. PubMed ID: 35920396
[TBL] [Abstract][Full Text] [Related]
18. The disruption of the CCDC6 - PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma.
Morra F; Merolla F; Damia G; Ricci F; Varricchio S; Ilardi G; Arenare L; Califano D; Napolitano V; Fruscio R; Melillo RM; Palazzo L; Celetti A
J Exp Clin Cancer Res; 2022 Aug; 41(1):245. PubMed ID: 35964058
[TBL] [Abstract][Full Text] [Related]
19. Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.
Wang L; Wang Q; Xu Y; Cui M; Han L
Curr Drug Targets; 2020; 21(2):167-178. PubMed ID: 31553293
[TBL] [Abstract][Full Text] [Related]
20. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
